eFFECTOR Therapeutics, Inc. Annual Operating Income (Loss) in USD from 2020 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
eFFECTOR Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2020 to 2023.
  • eFFECTOR Therapeutics, Inc. Operating Income (Loss) for the quarter ending March 31, 2024 was -$8.4M, a 12% increase year-over-year.
  • eFFECTOR Therapeutics, Inc. Operating Income (Loss) for the twelve months ending March 31, 2024 was -$32.7M, a 7.59% increase year-over-year.
  • eFFECTOR Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$33.8M, a 4.45% decline from 2022.
  • eFFECTOR Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$32.4M, a 1.59% decline from 2021.
  • eFFECTOR Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$31.9M, a 302% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
* An asterisk sign (*) next to the value indicates that the value is likely invalid.